Welcome to our dedicated page for Adapthealth news (Ticker: AHCO), a resource for investors and traders seeking the latest updates and insights on Adapthealth stock.
AdaptHealth Corp. reports developments tied to its healthcare-at-home business, which provides home medical equipment, medical supplies and related services. The company’s updates commonly address its Sleep Health, Respiratory Health, Diabetes Health and Wellness at Home categories, including sleep therapy equipment and supplies for obstructive sleep apnea, respiratory services, diabetes-related supplies and in-home wellness offerings.
Recurring AdaptHealth news also covers quarterly and annual results, financial guidance, patient census trends, digital patient engagement through myApp, referral and payor relationships, capitated partnerships, acquisitions and dispositions, credit facility activity, debt ratings and investor conference participation. The company serves Medicare, Medicaid and commercial insurance beneficiaries through a national operating network.
Cardinal Health (NYSE: CAH) announced definitive agreements to acquire AdaptHealth's Diabetes Health business and all of Strive Medical for a combined purchase price of approximately $360 million in cash, subject to working capital adjustments. The deals support Cardinal Health's at-Home Solutions growth strategy in diabetes management and urology.
According to Cardinal Health, AdaptHealth's Diabetes Health business serves more than 225,000 people annually via a centralized mail-order, direct-to-patient model, while Strive Medical serves more than 20,000 people annually in urology, wound care, ostomy and incontinence. Building on the earlier Advanced Diabetes Supply acquisition, Cardinal Health reports it has migrated all ADS volume to its at-Home Solutions network, onboarded nearly 500,000 new customers, and launched the ContinuCare Pathway digital referral program. The new transactions are subject to customary closing conditions, including regulatory approvals, and are expected to be accretive to non-GAAP EPS within 12 months after closing.
AdaptHealth (NASDAQ: AHCO) has signed a definitive agreement to divest its Diabetes Health business to Cardinal Health for $235 million in cash, subject to customary purchase price adjustments. The agreement was signed on July 19, 2026 and remains subject to Hart-Scott-Rodino antitrust review and other standard closing conditions.
According to AdaptHealth, the divestiture continues a multi‑year portfolio reshaping to focus on core Sleep Health, Respiratory Health, and supporting home medical equipment businesses, with an emphasis on delivering clinical value in patients’ homes. The company expects the transaction to increase capital flexibility for reinvestment in core businesses and debt reduction, and to improve its anticipated revenue growth profile and adjusted EBITDA margins going forward. AdaptHealth plans to provide a detailed update on financial and guidance implications, including treatment of Diabetes Health as a discontinued operation, on its Q2 2026 earnings call on August 4, 2026.
AdaptHealth (NASDAQ: AHCO) will release its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Management will host an earnings conference call at 8:30 a.m. ET for analysts and investors, with phone and webcast access plus a six-month replay on its investor relations website.
AdaptHealth (NASDAQ: AHCO) will participate in two investor conferences in May 2026: the Bank of America Global Healthcare Conference in Las Vegas on May 12, 2026 (fireside chat at 9:20 a.m. PT) and the RBC Global Healthcare Conference in New York on May 19, 2026 (fireside chat at 3:05 p.m. ET).
Webcast links will be available on the company’s Investor Relations website. AdaptHealth operates four reportable segments and serves about 4.5 million patients annually across ~670 locations in 48 states.
AdaptHealth (NASDAQ: AHCO) reported Q1 2026 results: net revenue $819.8M (+5.4% vs. Q1 2025) and organic revenue +9.1%. The company completed a major de novo expansion, grew registered myApp users to 412,000 (+26% QoQ), and closed a $1.1B refinancing in April 2026. Q1 adjusted EBITDA was $121.2M (down 5.3%); net loss attributable to AdaptHealth was $16.0M. Free cash flow was negative $27.5M. Management raised 2026 revenue guidance by $10M to $3.45B–$3.52B while maintaining adjusted EBITDA and free cash flow targets.
AdaptHealth (NASDAQ: AHCO) will release first quarter 2026 financial results before market open on Tuesday, May 5, 2026. Management will host a teleconference at 8:30 a.m. ET to discuss results with analysts and investors.
Dial-in numbers are provided with Conference ID AHCO1Q26; a webcast registration link and a replay available for six months on the company's Investor Relations site.
AdaptHealth (NASDAQ: AHCO) closed a $1.1 billion senior secured credit facility on April 13, 2026, comprising a $325M Term Loan, $325M Delayed Draw Term Loan, and $450M Revolver. The facility extends maturity to April 2031, lowers pricing (lowest tier from 1.50% to 1.125% over SOFR), and aims to reduce weighted average cost of debt by at least 25 basis points after redeeming 2028 notes.
AdaptHealth (NASDAQ: AHCO) will participate in two investor conferences in Miami in March 2026: the J.P. Morgan Global Leveraged Finance Conference on March 3, 2026 (fireside chat at 11:00 a.m. ET) and the Leerink Partners Global Healthcare Conference on March 9, 2026 (fireside chat at 2:20 p.m. ET).
Webcasts will be available via the company's Investor Relations website. AdaptHealth serves roughly 4.3 million patients annually through ~640 locations across 48 states in four reportable segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home.
AdaptHealth (NASDAQ: AHCO) reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year net revenue was $3,244.9M (down 0.5%); Adjusted EBITDA was $616.7M (down 10.5%). The company recorded a $128.0M non-cash goodwill impairment and reduced net debt by $250M for 2025.
2026 guidance: net revenue $3.44B–$3.51B, Adjusted EBITDA $680M–$730M, and free cash flow $175M–$225M. Management cited patient census records and operational investments supporting a large capitated contract.
AdaptHealth (NASDAQ: AHCO) will release fourth quarter and full year 2025 financial results before market open on Tuesday, February 24, 2026. Management will host a teleconference at 8:30 a.m. ET for analysts and investors with domestic and international dial-in numbers and Conference ID AHCO4Q25.
A live webcast requires registration and a replay will be available for six months on the company's Investor Relations site at www.adapthealth.com.